The study concludes that ASXL1 and ASXL2 mutations are frequent in pediatric AML, particularly in patients with t(8;21), and may occur as secondary genetic events that do not worsen prognosis, highlighting their role in leukemogenesis as epigenetic regulators [20]. Here, ASXL2 is linked to acute myeloid leukemia.